Syntax Bio
Chicago, United States · Founded 2021 · $15.0M raised
- Headquarters
- Chicago, Illinois
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
- Website
- syntaxbio.com
- Total Funding
- $15.0M
- Last Round
- $15.0M SeedSep 2024
- Rounds
- 1
About
Develops a CRISPR-based platform to program and accelerate stem cell differentiation, enabling scalable regenerative cell therapies for biopharma partners.
Summary
Syntax Bio is a Biotech company based in Chicago, United States, founded in 2021. It has raised $15.0M in total across 1 round, most recently a $15.0M Seed round in Sep 2024. Investors include Astellas Venture Management, Illumina Ventures and DCVC (Data Collab).
Tech & App Stack
1 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Sep 2024
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...